Zyversa Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Zyversa Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
OQB
ZyVersa Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify its accounting firm, and approve amendments to its equity incentive plan and warrant issuances.
OQB
DEF 14A: ZyVersa Therapeutics Seeks Stockholder Approval for Warrant Issuance to Bolster Financial Position
ZyVersa Therapeutics is seeking stockholder approval to issue up to 1,637,000 shares upon the exercise of certain warrants, aiming to raise approximately $3.4 million.
OQB
Zyversa Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
OQB
ZyVersa Therapeutics is holding its annual meeting to vote on key proposals including director election, auditor ratification, an equity incentive plan amendment, and approval for the issuance of common stock upon warrant exercises.
OQB
ZyVersa Therapeutics is seeking shareholder approval for a potential reverse stock split to maintain Nasdaq listing and attract investors amid a challenging biotech environment.
OQB
ZyVersa Therapeutics is asking shareholders to approve a potential reverse stock split to maintain its Nasdaq listing and attract investors, while also progressing its clinical trials for kidney and inflammatory diseases.